Delaware 153rd General Assembly Status: Introduced 1 D cosponsors

SJR 7 — SEBC/Pharmacy Benefit Managers/Utilize Strategies

Last action — Lieu/Substituted

  1. 1
    Introduced
  2. 2
    In Committee
  3. 3
    Passed Senate
  4. 4
    Passed House
  5. 5
    To Executive
  6. 6
    Enacted

This bill has been introduced in the Senate. Introduced May 21, 2025. It must pass committee before a floor vote.

Next likely step: a committee referral and hearing.

Odds of enactment

Low chance

Based on the sponsor, cosponsors, and committee posture, this bill has a low chance of becoming law.

Upgrade to see the exact probability and what's driving it.

A statistical estimate from our own model of past outcomes — an insight, not a guarantee. Policymaking is volatile.

Prognosis

Not enough signal yet

Not enough signal yet to read this bill's trajectory — we surface a likelihood only once there's real movement (stage, sponsorship, committee, or votes) to point to.

Based on stage, sponsorship breadth, committee status, recorded votes, and cross-state momentum — a description of the observable signals, not a prediction.

Summary

This Joint Resolution directs the State Employees Benefits Committee (SEBC) to utilize specific strategies and policies when interacting and contracting with Pharmacy Benefit Managers (PBM) in order to achieve lower cost pharacuetical drug benefit plans for the State. The Resolution requests the SEBC consider all of the following: 1. Drug cost transparency. 2. Adoption of a Pharmacy and Therapeutics Committee. 3. Any other supply chain tactics such as a reverse auction or transparency committee. 4. Formation of intra-state compacts with other states. 5. Paying similar prices for drugs paid by Medicare. 6. Require PBMs disclose administrative expenses for all pharmaceutical drugs. 7. Require PBMs to bid based on lowest pricing sources, not average wholesale price. 8. Require that all written agreements between the SEBC and PBMs that the SEBC is entitled to see the agreements between PBMs and pharmaceutical companies when those agreements the drug plans contracted on behalf of the SEBC. 9. Consider use of audits when the SEBC believes it should be entitled to information on the basis of transparency or clarity. The Resolution further directs the SEBC to prepare a report by December 1, 2025, to summarize any difficulties in implementing any of these policies.

Bill Text

We don't have the full text on file for this bill yet.

Read SJR 7 on the official Delaware source →

Action History

  1. Lieu/Substituted

Sponsors

Sponsorship breakdown

Export CSV (upgrade) →

1 sponsors · 0 co-sponsors · 61 not signed on

Sponsors (1)

Co-sponsors (0)

None.

Not signed on (61)

61 members have not signed on to this bill.

Show all 61 →

"Not signed on" means a member has not sponsored or co-sponsored this bill — it does not imply opposition. Members flagged Voted No have a recorded No vote on this bill.

Whip count is in markup. Polling the chamber and every recorded vote this session. Only the first open is slow. It’s instant for you after this. Calling the roll · Tallying · Engrossing

Subjects

healthcare health-insurance
Cross-referencing the record. Reading this bill against every other bill in the corpus by meaning, not keywords. Only the first open is slow. It’s instant for you after this. Matching · Ranking · Engrossing

Frequently asked questions

What does SJR 7 do?
This Joint Resolution directs the State Employees Benefits Committee (SEBC) to utilize specific strategies and policies when interacting and contracting with Pharmacy Benefit Managers (PBM) in order to achieve lower cost pharacuetical drug benefit plans for the State. The Resolution requests the SEBC consider all of the following: 1. Drug cost transparency. 2. Adoption of a Pharmacy and Therapeutics Committee. 3. Any other supply chain tactics such as a reverse auction or transparency committee. 4. Formation of intra-state compacts with other states. 5. Paying similar prices for drugs paid by Medicare. 6. Require PBMs disclose administrative expenses for all pharmaceutical drugs. 7. Require PBMs to bid based on lowest pricing sources, not average wholesale price. 8. Require that all written agreements between the SEBC and PBMs that the SEBC is entitled to see the agreements between PBMs and pharmaceutical companies when those agreements the drug plans contracted on behalf of the SEBC. 9. Consider use of audits when the SEBC believes it should be entitled to information on the basis of transparency or clarity. The Resolution further directs the SEBC to prepare a report by December 1, 2025, to summarize any difficulties in implementing any of these policies.
Who sponsors SJR 7?
SJR 7 is sponsored by Ray Seigfried (Democratic).
What is the current status of SJR 7?
This bill has been introduced in the Senate. Introduced May 21, 2025. It must pass committee before a floor vote.
Where can I track SJR 7?
Track SJR 7 free on One Click Politics — get push/email alerts when it moves.

Make your voice heard on SJR 7

Find the representatives who decide this bill and tell them where you stand — for yourself, or mobilize your whole list in one click with One Click Politics advocacy software.

Find my representatives → Run a campaign

Stay ahead of SJR 7

Last checked for changes 3 months ago · updated continuously

One Click Politics tracks every bill in Congress and all 50 states.

Track this bill →